GlassScriptPhysician profile
Raheel Jamal
NPI 1669463329
$4,734.55
in general payments reported to CMS, 2019-2025
22 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $26.77 · 2021: $61.52 · 2022: $276 · 2023: $317 · 2024: $3,805 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $1,146 · Food and Beverage: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $1,146.34 |
| Food and Beverage | $590.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,775.79 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $154.31 | 2019-2023 | Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.78 | 2019-2022 | |
| Baxter Healthcare | $108.12 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Glaxosmithkline, LLC. | $78.17 | 2019-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Inogen, INC. | $50.12 | 2022-2025 | Inogen |
| Gilead Sciences, INC. | $39.48 | 2023 | |
| Amgen INC. | $37.13 | 2022 | |
| La Jolla Pharmaceutical Company | $34.93 | 2022-2023 | Xerava |
| Merck Sharp & Dohme LLC | $34.90 | 2019-2023 | Recarbrio, Dificid, Zerbaxa |
| Insmed, INC. | $34.19 | 2022-2023 | Arikayce |
| Genzyme Corporation | $31.65 | 2023 | |
| Axsome Therapeutics, INC. | $29.81 | 2023 | Sunosi |
| Sunovion Pharmaceuticals INC. | $25.28 | 2019 | |
| United Therapeutics Corporation | $24.18 | 2021-2023 | Tyvaso |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $21.00 | 2023 | Yupelri |
| Jazz Pharmaceuticals INC. | $20.60 | 2021 | |
| Smith+Nephew, INC. | $19.28 | 2022 | |
| Philips North America LLC | $18.49 | 2023 | |
| Inspire Medical Systems, INC. | $18.00 | 2023 | Inspire |
| Electromed, INC. | $15.11 | 2024 | Smartvest |
| Phadia US INC. | $14.23 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raheel Jamal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.